Silodosin in the Treatment of the Signs and Symptoms of Benign Prostatic Hyperplasia: A 9-Month, Open-label Extension Study

Urology

Volumn 74, Issue 6, 2009, Pages 1318-1322

  Marks, Leonard S ^a   Gittelman, Marc C ^b   Hill, Lawrence A ^c   Volinn, Weining ^c   Hoel, Gary ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b South Florida Medical Research   (United States)

^c Watson Laboratories   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; SILODOSIN;

ADULT; AGED; ARTHRALGIA; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NOSE CONGESTION; ORTHOSTATIC HYPERTENSION; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RETROGRADE EJACULATION; RHINOPHARYNGITIS; SCORING SYSTEM; UNSPECIFIED SIDE EFFECT; UPPER RESPIRATORY TRACT INFECTION;

ADRENERGIC ALPHA-ANTAGONISTS; AGED; DOUBLE-BLIND METHOD; HUMANS; INDOLES; MALE; PROSTATIC HYPERPLASIA; TIME FACTORS;

EID: 70849089430     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2009.06.072     Document Type: Article

References (21)

1. Lepor H. Pathophysiology of lower urinary tract symptoms in the aging male population. Rev Urol. 7 (2005) S3-S11
2. Lepor H. Alpha blockers for the treatment of benign prostatic hyperplasia. Rev Urol. 9 (2007) 181-190
3. Schwinn D.A., and Roehrborn C.G. Alpha1-adrenoceptor subtypes and lower urinary tract symptoms. Int J Urol. 15 (2008) 193-199
4. Forray C., Bard J.A., Wetzel J.M., et al. The alpha 1-adrenergic receptor that mediates smooth muscle contraction in human prostate has the pharmacological properties of the cloned human alpha 1c subtype. Mol Pharmacol. 45 (1994) 703-708
5. Murata S., Taniguchi T., Takahashi M., et al. Tissue selectivity of KMD-3213, an alpha(1)-adrenoreceptor antagonist, in human prostate and vasculature. J Urol. 164 (2000) 578-583
6. Yamagishi R., Akiyama K., Nakamura S., et al. Effect of KMD-3213, an alpha 1A-adrenoceptor-selective antagonist, on the contractions of rabbit prostate and rabbit and rat aorta. Eur J Pharmacol. 315 (1996) 73-79
7. Chapple C., and Andersson K.E. Tamsulosin: an overview. World J Urol. 19 (2002) 397-404
8. Shibata K., Foglar R., Horie K., et al. KMD-3213, a novel, potent, alpha 1A-adrenoceptor-selective antagonist: characterization using recombinant human alpha 1-adrenoceptors and native tissues. Mol Pharmacol. 48 (1995) 250-258
9. Yamada S., Okura T., and Kimura R. In vivo demonstration of alpha(1A)-adrenoceptor subtype selectivity of KMD-3213 in rat tissues. J Pharmacol Exp Ther. 296 (2001) 160-167
10. Akiyama K., Noto H., Nishizawa O., et al. Effect of KMD-3213, an alpha1A-adrenoceptor antagonist, on the prostatic urethral pressure and blood pressure in male decerebrate dogs. Int J Urol. 8 (2001) 177-183
11. 1a-adrenoceptor antagonist silodosin in men with signs and symptoms of benign prostatic hyperplasia: pooled results of 2 phase 3 studies. J Urol. 181 (2009) 2634-2640
12. Chapple C.R. A comparison of varying alpha-blockers and other pharmacotherapy options for lower urinary tract symptoms. Rev Urol. 7 (2005) S22-S30
13. Milani S., and Djavan B. Lower urinary tract symptoms suggestive of benign prostatic hyperplasia: latest update on alpha-adrenoceptor antagonists. BJU Int. 95 (2005) 29-36
14. Noguchi Y., Ohtake A., Suzuki M., et al. In vivo study on the effects of alpha1-adrenoceptor antagonists on intraurethral pressure in the prostatic urethra and intraluminal pressure in the vas deferens in male dogs. Eur J Pharmacol. 580 (2008) 256-261
15. Michel M.C. Alpha1-adrenoceptors and ejaculatory function. Br J Pharmacol. 152 (2007) 289-290
16. Narayan P., and Lepor H. Long-term, open-label, phase III multicenter study of tamsulosin in benign prostatic hyperplasia. Urology 57 (2001) 466-470
17. Lepor H. Long-term evaluation of tamsulosin in benign prostatic hyperplasia: placebo-controlled, double-blind extension of phase III trial. Tamsulosin Investigator Group. Urology 51 (1998) 901-906
18. Lepor H. Phase III multicenter placebo-controlled study of tamsulosin in benign prostatic hyperplasia. Tamsulosin Investigator Group. Urology 51 (1998) 892-900
19. Roehrborn C.G., Van Kerrebroeck P., and Nordling J. Safety and efficacy of alfuzosin 10 mg once-daily in the treatment of lower urinary tract symptoms and clinical benign prostatic hyperplasia: a pooled analysis of three double-blind, placebo-controlled studies. BJU Int. 92 (2003) 257-261
20. Madersbacher S., Marszalek M., Lackner J., et al. The long-term outcome of medical therapy for BPH. Eur Urol. 51 (2007) 1522-1533
21. Barry M.J., Williford W.O., Chang Y., et al. Benign prostatic hyperplasia specific health status measures in clinical research: how much change in the American Urological Association symptom index and the benign prostatic hyperplasia impact index is perceptible to patients?. J Urol. 154 (1995) 1770-1774